1-naphthoyl-guanidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-naphthoyl-guanidine
• 英文别名: 1-naphthoylguanidine；N-carbamimidoylnaphthalene-1-carboxamide
• 化学式: C₁₂H₁₁N₃O
• 分子量: 213.239
• InChiKey: APOPAXUENTVHHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.5
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-naphthoyl-guanidine 在 碘 作用下， 生成 N-[5-[4-[[3-[[hydroxy(naphthalen-1-yl)methylidene]amino]-2H-1,2,4-thiadiazol-5-ylidene]amino]phenyl]imino-2H-1,2,4-thiadiazol-3-yl]naphthalene-1-carboximidic acid
  参考文献：
  名称：

  Fluorescent anion receptors with iminoylthiourea binding sites—selective hydrogen bond mediated recognition of CO 3 2− , HCO 3 − and HPO 4 2−

  摘要：

  A number of structurally simple, fluorescent sensor molecules based on the iminoylthiourea/1,2,4-thiadiazole unit are presented, which display extraordinarily strong fluorescence enhancement selectively upon complexation of HCO3-, CO32- and HPO42-. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)00324-0

文献信息

• Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
  申请人：——

  公开号：US20030013760A1

  公开（公告）日：2003-01-16

  Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them. Substituted 1-naphthoylguanidines of the formula I 1 in which R2 to R8 have the meanings indicated in the claims, are suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment and for the treatment of angina pectoris. They also preventively inhibit the pathophysiological processes in the formation of ischemically induced damage, in particular in the production of ischemically induced cardiac arrhythmias.

  取代的1-萘甲酰胍，其制备方法，作为药物或诊断工具的使用，以及含有它们的药物。在公式I中，取代的1-萘甲酰胍中R2至R8具有索赔中指示的含义，适用作为具有心脏保护成分的抗心律失常药物，用于梗死预防和梗死治疗以及心绞痛的治疗。它们还预防性地抑制缺血性损伤形成中的病理生理过程，特别是在缺血性诱发的心律失常的产生中。
• ANTIVIRAL COMPOUNDS AND METHODS
  申请人：Biotron Limited

  公开号：US20150313909A1

  公开（公告）日：2015-11-05

  The invention relates to compounds having antiviral activity and methods utilizing the compounds to treat viral infections.

  这项发明涉及具有抗病毒活性的化合物和利用这些化合物治疗病毒感染的方法。
• Antiviral compounds and methods
  申请人：Gage William Peter

  公开号：US20070099968A1

  公开（公告）日：2007-05-03

  The invention relates to compounds having antiviral activity and methods utilising the compounds to treat viral infections.

  该发明涉及具有抗病毒活性的化合物和利用这些化合物治疗病毒感染的方法。
• Antiviral Compounds and Methods
  申请人：Ewart Gary Dinneen

  公开号：US20090099239A1

  公开（公告）日：2009-04-16

  The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.

  本发明涉及具有抗病毒活性的新化合物和组合物。本发明还涉及在哺乳动物中治疗或预防病毒感染的方法。
• HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS
  申请人：Ewart Gary Dinneen

  公开号：US20100254942A1

  公开（公告）日：2010-10-07

  The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.

  本发明涉及具有抗病毒活性的新型组合物，特别是涉及对丙型肝炎病毒（HCV）具有协同作用的组合物。该发明还涉及延缓、减少或以其他方式抑制HCV的生长和/或功能活性的方法。